25 XP   0   0   10

US Stem Cell Inc
Buy, Hold or Sell?

Let's analyse US Stem Cell Inc together

PenkeI guess you are interested in US Stem Cell Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of US Stem Cell Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about US Stem Cell Inc

I send you an email if I find something interesting about US Stem Cell Inc.

Quick analysis of US Stem Cell Inc (30 sec.)










What can you expect buying and holding a share of US Stem Cell Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.02
Expected worth in 1 year
$-0.06
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
$-0.03
Return On Investment
-32,835.2%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%

1. Valuation of US Stem Cell Inc (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.03 - $0.01

Total Value Per Share

$-0.05 - $-0.01

2. Growth of US Stem Cell Inc (5 min.)




Is US Stem Cell Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$14.7m-$9.4m-$5.2m-35.7%

How much money is US Stem Cell Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$5m$1.7m52.3%
Net Profit Margin-4,028.6%-163.9%--

How much money comes from the company's main activities?

3. Financial Health of US Stem Cell Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#960 / 1011

Most Revenue
#638 / 1011

Most Profit
#363 / 1011

Most Efficient
#891 / 1011

What can you expect buying and holding a share of US Stem Cell Inc? (5 min.)

Welcome investor! US Stem Cell Inc's management wants to use your money to grow the business. In return you get a share of US Stem Cell Inc.

What can you expect buying and holding a share of US Stem Cell Inc?

First you should know what it really means to hold a share of US Stem Cell Inc. And how you can make/lose money.

Speculation

The Price per Share of US Stem Cell Inc is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of US Stem Cell Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in US Stem Cell Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.02. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of US Stem Cell Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-4,455.0%0.00-4,455.0%-0.01-5,124.5%0.00-4,686.3%0.00-4,305.8%
Usd Book Value Change Per Share-0.01-8,208.8%-0.01-8,208.8%0.003,273.4%0.00-2,383.5%0.00-23.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-8,208.8%-0.01-8,208.8%0.003,273.4%0.00-2,383.5%0.00-23.4%
Usd Price Per Share0.01-0.01-0.01-0.01-0.10-
Price to Earnings Ratio-1.12--1.12--1.17--2.07--36.32-
Price-to-Total Gains Ratio-0.61--0.61-1.83-8.74-24.65-
Price to Book Ratio-0.22--0.22--0.41--0.61--7.96-
Price-to-Total Gains Ratio-0.61--0.61-1.83-8.74-24.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (10000000 shares)-82,087.96-23,834.75
Gains per Year (10000000 shares)-328,351.83-95,338.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-328352-3283620-95339-95349
20-656704-6567140-190678-190688
30-985055-9850660-286017-286027
40-1313407-13134180-381356-381366
50-1641759-16417700-476695-476705
60-1970111-19701220-572034-572044
70-2298463-22984740-667373-667383
80-2626815-26268260-762712-762722
90-2955166-29551780-858051-858061
100-3283518-32835300-953390-953400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.018.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%10.08.00.055.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.018.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%10.08.00.055.6%

Fundamentals of US Stem Cell Inc

About US Stem Cell Inc

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Fundamental data was last updated by Penke on 2024-04-04 06:25:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of US Stem Cell Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit US Stem Cell Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -4,028.6% means that $-40.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of US Stem Cell Inc:

  • The MRQ is -4,028.6%. The company is making a huge loss. -2
  • The TTM is -4,028.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,028.6%TTM-4,028.6%0.0%
TTM-4,028.6%YOY-163.9%-3,864.7%
TTM-4,028.6%5Y-1,078.5%-2,950.1%
5Y-1,078.5%10Y-897.9%-180.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,028.6%-196.1%-3,832.5%
TTM-4,028.6%-211.9%-3,816.7%
YOY-163.9%-277.7%+113.8%
5Y-1,078.5%-432.9%-645.6%
10Y-897.9%-599.3%-298.6%
1.1.2. Return on Assets

Shows how efficient US Stem Cell Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • -4,858.1% Return on Assets means that US Stem Cell Inc generated $-48.58 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of US Stem Cell Inc:

  • The MRQ is -4,858.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4,858.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4,858.1%TTM-4,858.1%0.0%
TTM-4,858.1%YOY-5,604.4%+746.2%
TTM-4,858.1%5Y-3,625.9%-1,232.3%
5Y-3,625.9%10Y-2,429.7%-1,196.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,858.1%-13.3%-4,844.8%
TTM-4,858.1%-12.7%-4,845.4%
YOY-5,604.4%-11.8%-5,592.6%
5Y-3,625.9%-14.0%-3,611.9%
10Y-2,429.7%-15.9%-2,413.8%
1.1.3. Return on Equity

Shows how efficient US Stem Cell Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means US Stem Cell Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of US Stem Cell Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.0%+16.0%
YOY--15.1%+15.1%
5Y--19.7%+19.7%
10Y--20.5%+20.5%

1.2. Operating Efficiency of US Stem Cell Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient US Stem Cell Inc is operating .

  • Measures how much profit US Stem Cell Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • An Operating Margin of -2,096.9% means the company generated $-20.97  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of US Stem Cell Inc:

  • The MRQ is -2,096.9%. The company is operating very inefficient. -2
  • The TTM is -2,096.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,096.9%TTM-2,096.9%0.0%
TTM-2,096.9%YOY-111.2%-1,985.7%
TTM-2,096.9%5Y-635.1%-1,461.8%
5Y-635.1%10Y-645.6%+10.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,096.9%-290.9%-1,806.0%
TTM-2,096.9%-224.4%-1,872.5%
YOY-111.2%-288.3%+177.1%
5Y-635.1%-479.5%-155.6%
10Y-645.6%-625.2%-20.4%
1.2.2. Operating Ratio

Measures how efficient US Stem Cell Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 21.97 means that the operating costs are $21.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of US Stem Cell Inc:

  • The MRQ is 21.969. The company is inefficient in keeping operating costs low. -1
  • The TTM is 21.969. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ21.969TTM21.9690.000
TTM21.969YOY2.112+19.857
TTM21.9695Y7.537+14.432
5Y7.53710Y7.558-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.9693.110+18.859
TTM21.9693.266+18.703
YOY2.1123.783-1.671
5Y7.5375.657+1.880
10Y7.5587.783-0.225

1.3. Liquidity of US Stem Cell Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if US Stem Cell Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of US Stem Cell Inc:

  • The MRQ is 0.005. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.005. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.005TTM0.0050.000
TTM0.005YOY0.008-0.003
TTM0.0055Y0.057-0.052
5Y0.05710Y0.054+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0053.905-3.900
TTM0.0054.212-4.207
YOY0.0085.337-5.329
5Y0.0576.062-6.005
10Y0.0546.401-6.347
1.3.2. Quick Ratio

Measures if US Stem Cell Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of US Stem Cell Inc:

  • The MRQ is 0.001. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.001. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.0010.000
TTM0.001YOY0.008-0.007
TTM0.0015Y0.050-0.050
5Y0.05010Y0.049+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0013.572-3.571
TTM0.0014.001-4.000
YOY0.0085.364-5.356
5Y0.0506.009-5.959
10Y0.0496.287-6.238

1.4. Solvency of US Stem Cell Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of US Stem Cell Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare US Stem Cell Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 217.72 means that US Stem Cell Inc assets are financed with 21,772.0% credit (debt) and the remaining percentage (100% - 21,772.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of US Stem Cell Inc:

  • The MRQ is 217.720. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 217.720. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ217.720TTM217.7200.000
TTM217.720YOY106.511+111.209
TTM217.7205Y113.577+104.143
5Y113.57710Y84.257+29.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ217.7200.336+217.384
TTM217.7200.334+217.386
YOY106.5110.271+106.240
5Y113.5770.366+113.211
10Y84.2570.389+83.868
1.4.2. Debt to Equity Ratio

Measures if US Stem Cell Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of US Stem Cell Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.397-0.397
YOY-0.341-0.341
5Y-0.432-0.432
10Y-0.465-0.465

2. Market Valuation of US Stem Cell Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings US Stem Cell Inc generates.

  • Above 15 is considered overpriced but always compare US Stem Cell Inc to the Biotechnology industry mean.
  • A PE ratio of -1.12 means the investor is paying $-1.12 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of US Stem Cell Inc:

  • The EOD is -0.022. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.122. Based on the earnings, the company is expensive. -2
  • The TTM is -1.122. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.022MRQ-1.122+1.100
MRQ-1.122TTM-1.1220.000
TTM-1.122YOY-1.171+0.049
TTM-1.1225Y-2.067+0.945
5Y-2.06710Y-36.321+34.253
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.022-2.262+2.240
MRQ-1.122-2.599+1.477
TTM-1.122-2.674+1.552
YOY-1.171-4.133+2.962
5Y-2.067-6.258+4.191
10Y-36.321-6.171-30.150
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of US Stem Cell Inc:

  • The EOD is -0.210. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.522. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.522. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.210MRQ-10.522+10.311
MRQ-10.522TTM-10.5220.000
TTM-10.522YOY-2.794-7.728
TTM-10.5225Y-2.895-7.627
5Y-2.89510Y-65.878+62.983
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.210-2.913+2.703
MRQ-10.522-3.275-7.247
TTM-10.522-3.508-7.014
YOY-2.794-5.620+2.826
5Y-2.895-8.306+5.411
10Y-65.878-8.854-57.024
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of US Stem Cell Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.22 means the investor is paying $-0.22 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of US Stem Cell Inc:

  • The EOD is -0.004. Based on the equity, the company is expensive. -2
  • The MRQ is -0.218. Based on the equity, the company is expensive. -2
  • The TTM is -0.218. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.004MRQ-0.218+0.213
MRQ-0.218TTM-0.2180.000
TTM-0.218YOY-0.406+0.189
TTM-0.2185Y-0.606+0.388
5Y-0.60610Y-7.959+7.353
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0041.858-1.862
MRQ-0.2182.090-2.308
TTM-0.2182.091-2.309
YOY-0.4062.866-3.272
5Y-0.6063.488-4.094
10Y-7.9593.836-11.795
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of US Stem Cell Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.008-0.0080%0.003-351%-0.002-71%0.000-100%
Book Value Per Share---0.023-0.0230%-0.015-36%-0.016-29%-0.016-32%
Current Ratio--0.0050.0050%0.008-36%0.057-91%0.054-91%
Debt To Asset Ratio--217.720217.7200%106.511+104%113.577+92%84.257+158%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%
Eps---0.004-0.0040%-0.005+15%-0.005+5%-0.004-3%
Free Cash Flow Per Share--0.0000.0000%-0.002+352%-0.001+82%-0.001+75%
Free Cash Flow To Equity Per Share--0.0000.0000%-0.003+4835%-0.001+1752%0.000+716%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.014--------
Intrinsic Value_10Y_min---0.026--------
Intrinsic Value_1Y_max--0.000--------
Intrinsic Value_1Y_min---0.002--------
Intrinsic Value_3Y_max--0.000--------
Intrinsic Value_3Y_min---0.006--------
Intrinsic Value_5Y_max--0.003--------
Intrinsic Value_5Y_min---0.011--------
Market Cap64150.701-4900%3207535.0403207535.0400%3849042.048-17%5478469.848-41%62174859.215-95%
Net Profit Margin---40.286-40.2860%-1.639-96%-10.785-73%-8.979-78%
Operating Margin---20.969-20.9690%-1.112-95%-6.351-70%-6.456-69%
Operating Ratio--21.96921.9690%2.112+940%7.537+191%7.558+191%
Pb Ratio-0.004+98%-0.218-0.2180%-0.406+87%-0.606+178%-7.959+3559%
Pe Ratio-0.022+98%-1.122-1.1220%-1.171+4%-2.067+84%-36.321+3136%
Price Per Share0.000-4900%0.0050.0050%0.006-17%0.009-41%0.097-95%
Price To Free Cash Flow Ratio-0.210+98%-10.522-10.5220%-2.794-73%-2.895-72%-65.878+526%
Price To Total Gains Ratio-0.012+98%-0.609-0.6090%1.833-133%8.738-107%24.648-102%
Quick Ratio--0.0010.0010%0.008-91%0.050-99%0.049-99%
Return On Assets---48.581-48.5810%-56.044+15%-36.259-25%-24.297-50%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share---0.008-0.0080%0.003-351%-0.002-71%0.000-100%
Usd Book Value---14745396.000-14745396.0000%-9479396.000-36%-10433138.000-29%-9964717.300-32%
Usd Book Value Change Per Share---0.008-0.0080%0.003-351%-0.002-71%0.000-100%
Usd Book Value Per Share---0.023-0.0230%-0.015-36%-0.016-29%-0.016-32%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.0040%-0.005+15%-0.005+5%-0.004-3%
Usd Free Cash Flow---304852.000-304852.0000%-1377828.000+352%-554018.600+82%-532644.600+75%
Usd Free Cash Flow Per Share--0.0000.0000%-0.002+352%-0.001+82%-0.001+75%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.003+4835%-0.001+1752%0.000+716%
Usd Market Cap64150.701-4900%3207535.0403207535.0400%3849042.048-17%5478469.848-41%62174859.215-95%
Usd Price Per Share0.000-4900%0.0050.0050%0.006-17%0.009-41%0.097-95%
Usd Profit---3305425.000-3305425.0000%-5035130.000+52%-3445362.400+4%-2981733.900-10%
Usd Revenue--82049.00082049.0000%3072293.000-97%2640922.000-97%2615150.100-97%
Usd Total Gains Per Share---0.008-0.0080%0.003-351%-0.002-71%0.000-100%
 EOD+2 -6MRQTTM+0 -0YOY+11 -205Y+10 -2110Y+6 -25

3.2. Fundamental Score

Let's check the fundamental score of US Stem Cell Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.022
Price to Book Ratio (EOD)Between0-1-0.004
Net Profit Margin (MRQ)Greater than0-40.286
Operating Margin (MRQ)Greater than0-20.969
Quick Ratio (MRQ)Greater than10.001
Current Ratio (MRQ)Greater than10.005
Debt to Asset Ratio (MRQ)Less than1217.720
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-48.581
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of US Stem Cell Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5012.041
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets68
Total Liabilities14,813
Total Stockholder Equity-14,745
 As reported
Total Liabilities 14,813
Total Stockholder Equity+ -14,745
Total Assets = 68

Assets

Total Assets68
Total Current Assets68
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 5
Net Receivables 4
Inventory 1
Other Current Assets 58
Total Current Assets  (as reported)68
Total Current Assets  (calculated)68
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,078
Long-term Liabilities736
Total Stockholder Equity-14,745
Total Current Liabilities
Short-term Debt 8,265
Short Long Term Debt 8,265
Accounts payable 1,625
Other Current Liabilities 4,185
Total Current Liabilities  (as reported)14,078
Total Current Liabilities  (calculated)22,340
+/- 8,262
Long-term Liabilities
Long term Debt 682
Other Liabilities 54
Long-term Liabilities  (as reported)736
Long-term Liabilities  (calculated)736
+/-0
Total Stockholder Equity
Common Stock634
Retained Earnings -142,517
Other Stockholders Equity 127,137
Total Stockholder Equity (as reported)-14,745
Total Stockholder Equity (calculated)-14,745
+/-0
Other
Capital Stock634
Cash and Short Term Investments 5
Common Stock Shares Outstanding 591,558
Current Deferred Revenue3
Liabilities and Stockholders Equity 68
Net Debt 8,942
Net Invested Capital -5,799
Net Tangible Assets -14,745
Net Working Capital -14,010
Short Long Term Debt Total 8,947



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
2,540
921
729
5,869
6,508
11,324
1,855
1,866
309
268
162
86
205
229
428
1,598
1,817
90
88
90
68
689088901,8171,598428229205861622683091,8661,85511,3246,5085,8697299212,540
   > Total Current Assets 
2,231
635
182
5,445
5,365
6,178
1,226
443
193
154
106
67
141
116
329
1,103
1,507
66
88
66
68
686688661,5071,103329116141671061541934431,2266,1785,3655,4451826352,231
       Cash And Cash Equivalents 
2,231
635
182
5,158
5,025
5,492
50
75
3
37
271
46
37
58
271
987
1,357
0
19
19
5
5191901,35798727158374627137375505,4925,0255,1581826352,231
       Net Receivables 
0
0
0
72
80
53
57
142
1
3
1
20
95
35
16
43
18
48
54
48
4
448544818431635952013114257538072000
       Other Current Assets 
0
0
0
54
96
261
724
26
34
50
42
1
9
5
0
3
38
0
0
10
58
5810003830591425034267242619654000
   > Long-term Assets 
0
0
0
425
1,143
5,146
629
1,423
116
115
56
19
63
113
99
495
311
24
0
24
0
024024311495991136319561151161,4236295,1461,143425000
       Property Plant Equipment 
0
0
0
414
527
445
281
104
47
15
2
9
13
14
21
450
243
7
7
7
0
0777243450211413921547104281445527414000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
41
89
68
35
58
24
0
0
0
000245835688941000000000000
       Long-term Assets Other 
0
0
0
10
616
4,702
348
1,319
69
99
55
10
10
10
10
10
10
0
0
-24
0
0-24001010101010105599691,3193484,70261610000
> Total Liabilities 
1,752
1,475
2,586
1,283
2,197
16,829
16,091
15,279
12,325
12,279
14,758
13,833
11,099
7,951
8,446
8,698
8,699
9,569
11,667
9,569
14,813
14,8139,56911,6679,5698,6998,6988,4467,95111,09913,83314,75812,27912,32515,27916,09116,8292,1971,2832,5861,4751,752
   > Total Current Liabilities 
0
0
0
1,235
2,161
13,864
15,036
10,001
11,292
12,279
14,147
13,429
11,099
5,705
6,164
6,463
5,917
8,751
10,848
8,751
14,078
14,0788,75110,8488,7515,9176,4636,1645,70511,09913,42914,14712,27911,29210,00115,03613,8642,1611,235000
       Short-term Debt 
0
0
0
0
0
6,671
7,899
4,052
4,957
5,098
2,365
5,546
5,365
2,407
2,974
3,246
2,455
0
0
5,425
8,265
8,2655,425002,4553,2462,9742,4075,3655,5462,3655,0984,9574,0527,8996,67100000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3,032
680
2,974
3,246
2,455
5,425
6,725
7,294
8,265
8,2657,2946,7255,4252,4553,2462,9746803,032000000000000
       Accounts payable 
0
0
0
225
804
2,134
1,701
1,912
2,050
2,378
2,619
2,382
1,992
1,399
1,186
1,378
1,183
1,188
1,282
1,188
1,625
1,6251,1881,2821,1881,1831,3781,1861,3991,9922,3822,6192,3782,0501,9121,7012,134804225000
       Other Current Liabilities 
0
0
0
1,010
1,357
4,512
4,971
3,530
3,819
465
8,698
478
1,220
1,827
1,877
1,499
1,856
511
468
2,093
4,185
4,1852,0934685111,8561,4991,8771,8271,2204788,6984653,8193,5304,9714,5121,3571,010000
   > Long-term Liabilities 
0
0
0
48
37
2,965
1,056
5,277
1,033
7,476
611
404
7,357
2,246
2,283
2,235
2,783
819
820
819
736
7368198208192,7832,2352,2832,2467,3574046117,4761,0335,2771,0562,9653748000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,216
2,211
1,916
2,596
0
0
0
0
00002,5961,9162,2112,2160000000000000
       Other Liabilities 
0
0
0
48
37
22
11
1
0
0
611
404
0
30
72
319
187
63
60
57
54
545760631873197230040461100111223748000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72
219
87
0
0
0
0
0000872197200000000000000
> Total Stockholder Equity
788
-554
-1,857
4,586
4,311
-5,505
-14,236
-13,412
-12,016
-12,010
-14,596
-13,747
-10,894
-7,721
-8,019
-7,100
-6,882
-9,479
-11,579
-9,479
-14,745
-14,745-9,479-11,579-9,479-6,882-7,100-8,019-7,721-10,894-13,747-14,596-12,010-12,016-13,412-14,236-5,5054,3114,586-1,857-554788
   Common Stock
0
0
0
12
13
13
16
20
38
96
182
380
581
2
127
342
378
418
436
418
634
634418436418378342127258138018296382016131312000
   Retained Earnings -142,517-133,624-136,515-133,624-129,789-127,628-124,147-122,076-120,434-118,181-115,038-111,021-106,324-100,629-96,785-82,580-64,513-51,332-44,005-37,877-32,449
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
103,819
108,939
114,555
115,981
120,186
122,528
0
0
0
0
0000122,528120,186115,981114,555108,939103,81900000000000
   Treasury Stock0000000-2220000000000000
   Other Stockholders Equity 
33,237
37,323
42,148
56,088
68,810
77,061
82,533
87,196
94,270
98,915
100,260
104,034
108,939
114,333
115,981
120,186
122,528
0
0
123,727
127,137
127,137123,72700122,528120,186115,981114,333108,939104,034100,26098,91594,27087,19682,53377,06168,81056,08842,14837,32333,237



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue82
Cost of Revenue-24
Gross Profit5858
 
Operating Income (+$)
Gross Profit58
Operating Expense-1,779
Operating Income-1,720-1,720
 
Operating Expense (+$)
Research Development0
Selling General Administrative1,779
Selling And Marketing Expenses0
Operating Expense1,7791,779
 
Net Interest Income (+$)
Interest Income0
Interest Expense-690
Other Finance Cost-0
Net Interest Income-690
 
Pretax Income (+$)
Operating Income-1,720
Net Interest Income-690
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,858-583
EBIT - interestExpense = -2,410
-2,858
-2,615
Interest Expense690
Earnings Before Interest and Taxes (EBIT)-1,720-2,168
Earnings Before Interest and Taxes (EBITDA)-1,720
 
After tax Income (+$)
Income Before Tax-2,858
Tax Provision-0
Net Income From Continuing Ops-2,858-2,858
Net Income-3,305
Net Income Applicable To Common Shares-2,858
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,803
Total Other Income/Expenses Net-1,137690
 

Technical Analysis of US Stem Cell Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of US Stem Cell Inc. The general trend of US Stem Cell Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine US Stem Cell Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of US Stem Cell Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
US Stem Cell Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of US Stem Cell Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

US Stem Cell Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of US Stem Cell Inc. The current macd is 0.0000.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the US Stem Cell Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for US Stem Cell Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the US Stem Cell Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
US Stem Cell Inc Daily Moving Average Convergence/Divergence (MACD) ChartUS Stem Cell Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of US Stem Cell Inc. The current adx is 67.14.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell US Stem Cell Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
US Stem Cell Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of US Stem Cell Inc. The current sar is 0.00010112.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
US Stem Cell Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of US Stem Cell Inc. The current rsi is 12.04. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
US Stem Cell Inc Daily Relative Strength Index (RSI) ChartUS Stem Cell Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of US Stem Cell Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the US Stem Cell Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
US Stem Cell Inc Daily Stochastic Oscillator ChartUS Stem Cell Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of US Stem Cell Inc. The current cci is -66.66666667.

US Stem Cell Inc Daily Commodity Channel Index (CCI) ChartUS Stem Cell Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of US Stem Cell Inc. The current cmo is 0.

US Stem Cell Inc Daily Chande Momentum Oscillator (CMO) ChartUS Stem Cell Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of US Stem Cell Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
US Stem Cell Inc Daily Williams %R ChartUS Stem Cell Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of US Stem Cell Inc.

US Stem Cell Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of US Stem Cell Inc. The current atr is 0.0000.

US Stem Cell Inc Daily Average True Range (ATR) ChartUS Stem Cell Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of US Stem Cell Inc. The current obv is -17,434,274.

US Stem Cell Inc Daily On-Balance Volume (OBV) ChartUS Stem Cell Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of US Stem Cell Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
US Stem Cell Inc Daily Money Flow Index (MFI) ChartUS Stem Cell Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for US Stem Cell Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

US Stem Cell Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of US Stem Cell Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5012.041
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of US Stem Cell Inc with someone you think should read this too:
  • Are you bullish or bearish on US Stem Cell Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about US Stem Cell Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about US Stem Cell Inc

I send you an email if I find something interesting about US Stem Cell Inc.


Comments

How you think about this?

Leave a comment

Stay informed about US Stem Cell Inc.

Receive notifications about US Stem Cell Inc in your mailbox!